INTRODUCTION {#s1}
============

It is estimated that up to 50% of human cancers are caused by infectious agents. Viruses are responsible for 10%--15% particularly ([@R1]). As one of the most common cancers worldwide, the pathogenesis of gastric cancer (GC) remains unclear ([@R2]). *Helicobacter pylori* and Epstein-Barr virus (EBV) have been recognized as infectious agents, and the potential mechanisms inducing gastric carcinogenesis are well established ([@R3]--[@R7]). Almost 50% of the global population is infected with *H. pylori*, and 1% of them develop GC ([@R7]). Similarly, EBV is estimated to be responsible for 5.6%--19.5% of cases with GC globally ([@R8]).

In addition to *H. pylori* and EBV, other viruses might play potential roles in gastric carcinogenesis. A potential association between hepatitis B virus (HBV) and the risk of GC was found in a case--control study ([@R9]). Del Moral-Hernández et al. ([@R10]) considered human cytomegalovirus (HCMV) infection might contribute to gastritis and GC etiology. The role of HPV in GC is also indicated in several studies ([@R11]--[@R14]). Several sporadic studies sought to attach viruses other than EBV to the risk of GC; however, there is no comprehensive review to identify any potentially causative virus until now. Therefore, we performed this systematic review and meta-analysis to clarify the associations between the prevalence of viruses other than EBV and the risk of GC based on epidemiological studies.

METHODS {#s2}
=======

Reporting {#s2-1}
---------

This meta-analysis was conducted according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 2000 statements, and a flow diagram was plotted ([@R15],[@R16]). Details of study design have been reported elsewhere ([@R17]).

Literature search {#s2-2}
-----------------

PubMed, Embase, Cochrane Library, and Web of Science databases were searched up to January 25, 2019, and search was updated on April 6, 2020. The PubMed was searched with the following search terms, (("stomach neoplasms"\[MeSH Terms\] OR ("stomach"\[All Fields\] AND "neoplasms"\[All Fields\]) OR "stomach neoplasms"\[All Fields\] OR ("gastric"\[All Fields\] AND "cancer"\[All Fields\]) OR "GC"\[All Fields\]) AND ("viruses"\[MeSH Terms\] OR "viruses"\[All Fields\] OR "virus"\[All Fields\])) NOT ("animal"\[Filter\] OR "review"\[Publication Type\] OR "case reports"\[Publication Type\] OR "letter"\[Publication Type\] OR "comment"\[Publication Type\]) ([@R17]). A similar search strategy was applied in searching published literature in Embase, Cochrane Library, and Web of Science databases.

Eligibility {#s2-3}
-----------

The studies that compared the positivity of any virus between cases with histologically proven GC with healthy or nonmalignant controls were eligible. The patients with gastric lymphoma, gastrointestinal stromal tumor, and squamous cell carcinoma were ineligible. Any type of cohort study, cross-sectional study, or case--control study was considered. The detection of viruses was performed in cases and controls based on either blood/serum or tissue specimens. Any targeted virus other than EBV was eligible in this systematic review. There was no limitation on the race, sex, age, cancer stage, and treatment strategy. Only those studies with extractable data were considered for analysis ([@R17]). For overlap study, only the most recent study or the study with the larger number of participants was included.

Selection and quality assessment {#s2-4}
--------------------------------

Two reviewers separately browsed the titles/abstracts and assessed the potentially eligible full-texts according to the predefined inclusion and exclusion criteria. Discrepancies were resolved by consensus with a third reviewer. Risk of bias assessment of all included studies was independently performed by 2 reviewers, according to the Newcastle-Ottawa Scale ([@R18]).

Data extraction {#s2-5}
---------------

Data were extracted independently by 2 reviewers. Extracted items included general study characteristics (publication year, country, and study design), characteristics of the study population (sample size, sex, and age), and types of measurements (specimen types and viruses detection methods). Numbers of cases and controls were extracted from publications. Included study where different test methods were applied or various types of viruses were investigated was treated as more than 1 study. For study that had taken paired corresponding normal tissues (PCNTs) from the same patients with GC and noncancer gastric mucosa samples from patients without cancer as controls simultaneously, only data about patients without cancer were extracted. Potential discrepancies in extracted items if any were resolved by further review and discussion ([@R17]).

Statistical analysis {#s2-6}
--------------------

The STATA 12.0 and the PASS 11 software were used for statistical analysis ([@R19],[@R20]). All analysis was based on individual virus. The pooled prevalence of any virus infection in patients with GC was combined for rate, with 95% confidence intervals (CIs). The pooled odds ratios (ORs) and their 95% CIs for virus prevalence were calculated between patients with GC and any controls by fixed or random effect model where suitable, and reanalysis was conducted after excluding subjects with known *H. pylori* and EBV positive. Two-sided *P* values for the pooled ORs \< 0.05 were considered as statistical significance. I^2^ was estimated to evaluate the heterogeneity. Any *P* value \< 0.05 of Begg or Egger test was considered as significance of publication bias. The leave-one-out method was applied for sensitivity analysis. In addition, L\'Abbé plot and Galbraith plot were used to observe the heterogeneity. For an individual study, the power (1--β) was estimated by the PASS 11 software ([@R20]). Two-sided Z test (pooled) was provided with α = 0.05.

RESULTS {#s3}
=======

Systematic literature search and general information {#s3-1}
----------------------------------------------------

Forty-one studies were included in this meta-analysis finally (Figure [1](#F1){ref-type="fig"}) ([@R10]--[@R14],[@R21]--[@R56]). Eleven kinds of viruses were involved including HBV, hepatitis C virus (HCV), hepatitis E virus (HEV), HCMV, HIV, human papillomavirus (HPV), herpes simplex virus, human T-cell lymphotropic virus type 1 (HTLV-1), John Cunningham virus (JCV), and human parvovirus (B19 and human bocavirus) (Table [1](#T1){ref-type="table"}). The comparison of prevalence viruses between patients with GC and any controls with corresponding estimated power is summarized in Table [2](#T2){ref-type="table"}. Quality assessment scoring of studies is tabulated in Table [3](#T3){ref-type="table"} with Newcastle-Ottawa Scale scores ranging from 6 to 9. Meta-analysis was conducted in studies involving HBV, HCMV, HPV, HTLV-1, and JCV.

![The flowchart of the literature search.](ct9-11-e00201-g001){#F1}

###### 

Characteristics of studies on virus other than Epstein-Barr virus and risk of GC
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###### 

Comparison of the prevalence of virus other than Epstein-Barr virus between GC and any controls
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###### 

Methodological quality by the Newcastle-Ottawa Scale
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HBV and GC {#s3-2}
----------

The 7 studies that investigated the relationship between HBV and GC involved 53,396 patients with GC and 325,458 any controls ([@R26],[@R27],[@R35],[@R47],[@R52],[@R55],[@R56]). The pooled HBV prevalence in GC was 7.6% (95% CI 4.6%--10.6%, random model, heterogeneity *P* \< 0.001). Association between HBV infection and the risk of GC was observed (OR = 1.56, 95% CI 1.18--2.07, random model, heterogeneity *P* \< 0.001) (see Figure 1a, Supplementary Digital Content 1, <http://links.lww.com/CTG/A299>). Two studies investigated the coinfection of *H. pylori* ([@R26],[@R52]), and data could be extracted completely for cases and controls from only 1 study ([@R52]). We reanalyzed after excluding subjects with known *H. pylori* positive, and association between HBV infection and the risk of GC was observed (OR = 1.39, 95% CI 1.11--1.75, random model, heterogeneity *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}a).

![The forest plots of the comparison on virus prevalence between patients with gastric cancer and any controls after excluding subjects with known *H. pylori* and EBV positive: (**a**) the forest plot for HBV; (**b**) HCMV: Jin \[1--5\]: different sequences of HCMV genome were detected; Zhang \[1--2\]: IgG or IgM was detected; (**c**) the forest plot for HPV: Kamangar \[1--3\]:different subtypes of HPV were investigated; Ma \[1--2\]:different test methods were used; and (**d**) the forest plot for JCV: Jang \[1--2\]: different test methods were used; Murai \[1--3\]: different sequences of JCV genome were detected by Southern blot; Murai \[4\]: T-Ag were detected by immunohistochemistry; Shin \[1--3\]: different sequences of JCV genome were detected. CI, confidence interval; EBV, Epstein-Barr virus; HCMV, human cytomegalovirus; HPV, human papillomavirus; JCV, John Cunningham virus; OR, odds ratio; T-Ag, transforming antigen.](ct9-11-e00201-g008){#F2}

According to the different study regions and sample size, subgroup analysis was conducted before and after excluding subjects with known *H. pylori* positive (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). The result showed that HBV infection was still related to the risk of GC after 1 study from United States was dropped along with a decrease of heterogeneity, which indicated that study location might be responsible for the heterogeneity (OR = 1.18, 95% CI 1.08--1.29, random model, heterogeneity *P* = 0.344) (Table [5](#T5){ref-type="table"}).
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Subgroup analysis of HCMV, HPV, and JCV prevalence between GC and any controls before excluding subjects with known *H. pylori* and Epstein-Barr virus positive
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###### 

Subgroup analysis of HCMV, HPV, and JCV prevalence between GC and any controls after excluding subjects with known *H. pylori* and Epstein-Barr virus positive
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HCMV and GC {#s3-3}
-----------

Five studies sought to detect HCMV in GC with 682 samples (265 for cases with GC, 417 for noncancer controls) ([@R10],[@R26],[@R30],[@R37],[@R51]). The pooled HCMV prevalence in GC was 43.1% (95% CI 14.2%--72.0%, random model, heterogeneity *P* \< 0.001). The pooled OR showed that HCMV infection was highly related to the risk of GC (OR = 2.09, 95% CI 1.14--3.84, random model, heterogeneity *P* = 0.058) (see Figure 1b, Supplementary Digital Content 1, <http://links.lww.com/CTG/A299>). Two studies investigated the coinfection of *H. pylori* and EBV ([@R10],[@R26]), and data could been extracted completely for cases and controls from only 1 study ([@R10]). We reanalyzed after excluding subjects with known *H. pylori* and EBV positive, and association between HCMV infection and the risk of GC was observed (OR = 2.25, 95% CI 1.14--4.43, random model, heterogeneity *P* = 0.079) (Figure [2](#F2){ref-type="fig"}b).

According to the different study regions, control type, and test material, subgroup analysis was conducted before and after excluding subjects with known *H. pylori* and EBV positive (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). Compared with noncancer healthy and benign gastric disease controls, the prevalence of HCMV in patients with GC was higher than that in PCNT controls significantly. By comparison with serum samples, association between HCMV infection and the risk of GC was observed in gastric tissues. Study location might be responsible for the heterogeneity among the studies from China (I^2^ = 23.2%, *P* = 0.252) and other regions (I^2^ = 66.4%, *P* = 0.051) (Table [5](#T5){ref-type="table"}).

HPV and GC {#s3-4}
----------

Fourteen studies investigated the prevalence of HPV including 901 patients with GC and 1,205 any controls ([@R11]--[@R14],[@R22],[@R25],[@R31],[@R39],[@R43],[@R46],[@R49],[@R50],[@R53],[@R54]). The pooled HPV prevalence in GC was 23.6% (95% CI 15.5%--31.6%, random model, heterogeneity *P* \< 0.001). Association between HPV infection and the risk of GC was observed (OR = 1.53, 95% CI 1.00--2.33, random model, heterogeneity *P* = 0.002) (see Figure 1c, Supplementary Digital Content 1, <http://links.lww.com/CTG/A299>). Five studies investigated the coinfection of *H. pylori* or EBV without extractable data for cases and controls ([@R12],[@R13],[@R49],[@R53],[@R54]). We reanalyzed after excluding controls with *H. pylori*-positive gastritis in the study by Bozdayi et al., and association still existed (OR = 1.63, 95% CI 1.05--2.54, random model, heterogeneity *P* = 0.002) (Figure [2](#F2){ref-type="fig"}c) ([@R53]).

According to publication year, study regions, sample size, control type, test material, case type, and subtype of HPV, subgroup analysis was conducted before and after excluding subjects with known *H. pylori* positive (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). HPV infection was associated with GC for studies from China, publication year from 2000 to 2009, and if tissue specimens were tested. Compared with noncancer healthy and benign gastric disease controls, the prevalence of HPV in patients with GC was higher than that in PCNT controls significantly. Statistically significant association between HPV-16 infection and the risk of GC was also observed (OR = 2.42, 95% CI 1.00--5.83, random model, heterogeneity *P* = 0.003) (Table [5](#T5){ref-type="table"}).

HTLV-1 and GC {#s3-5}
-------------

Serum antibodies to HTLV-1 were measured in 4,293 serum samples (463 cases with GC, 3,831 noncancer controls) in 2 studies ([@R44],[@R45]). The pooled HTLV-1 prevalence was 6.20% (95% CI −5.3% to 17.7%, random model, heterogeneity *P* \< 0.001). No association was observed between HTLV-1 infection and the risk of GC (OR = 0.89, 95% CI 0.61--1.30, fixed model, heterogeneity *P* = 0.272) (see Figure 1d, Supplementary Digital Content 1, <http://links.lww.com/CTG/A299>).

JCV and GC {#s3-6}
----------

Nine studies involving 1,356 tissue samples (692 for GC and 664 for any controls) investigated the association between JCV and GC ([@R23],[@R24],[@R28],[@R29],[@R33],[@R38],[@R41],[@R42],[@R48]). The pooled JCV prevalence was 35.6% (95% CI 23.2%--48.1%, random model, heterogeneity *P* \< 0.001). Significant correlation between JCV infection and the risk of GC was revealed (OR = 2.28, 95% CI 1.14--4.56, random model, heterogeneity *P* \< 0.001) (see Figure 1e, Supplementary Digital Content 1, <http://links.lww.com/CTG/A299>). Three studies investigated the coinfection of *H. pylori* or EBV, and data could be extracted completely for cases and controls from only 1 study ([@R23],[@R41],[@R48]). Subjects with JCV infection were not accompanied with EBV coinfection in the study by Cherati et al. ([@R23]). We reanalyzed after excluding *H. pylori*-positive controls in the study by Selgrad et al. and subjects with EBV positive in the study by Yamaoka et al., and association still existed (OR = 2.52, 95% CI 1.26--5.04, random model, heterogeneity *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}d) ([@R41],[@R48]).

According to the publication year, study regions, sample size, control type, and the test method, subgroup analysis was conducted before and after excluding subjects with known *H. pylori* and EBV positive (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). JCV infection was associated with GC for studies from non-Asian regions, publication year from 2010 to 2019, and using polymerase chain reaction method or immunohistochemistry method. Compared with noncancer healthy and benign gastric disease controls, the prevalence of JCV in GC was higher than PCNT controls significantly (Table [5](#T5){ref-type="table"}).

Sensitivity, publication bias, and heterogeneity {#s3-7}
------------------------------------------------

Sensitivity and publication bias were conducted for studies involving HBV, HCMV, HPV, and JCV. In the leave-one-out analysis, we found that the pooled ORs were always consistent by excluding any single study, which verified the reliability of this meta-analysis statistically (Figure [3](#F3){ref-type="fig"}). Because all *P* values for Begg test and Egger test were \>0.05, it meant that no evidence for publication bias was indicated. The L\'Abbé plot and the Galbraith plot demonstrated the existence of heterogeneity in this meta-analysis for HBV, HCMV, HPV, and JCV. The Begg funnel plot, Egger regression plot, L\'Abbé plot, and Galbraith plot of the all-included meta-analysis are shown in Supplementary Figures 2--5, respectively (Supplementary Digital Content 2--5, <http://links.lww.com/CTG/A294>, <http://links.lww.com/CTG/A295>, <http://links.lww.com/CTG/A296>, <http://links.lww.com/CTG/A297>).

![Sensitivity analysis of the meta-analysis: (**a**) HBV; (**b**) HCMV; (**c**) HPV; and (**d**) JCV. CI, confidence interval; HBV, hepatitis B virus; HCMV, human cytomegalovirus; JCV, John Cunningham virus.](ct9-11-e00201-g013){#F3}

DISCUSSION {#s4}
==========

GC is one of the infection-associated malignancies, and the potential mechanisms inducing gastric carcinogenesis are well established for *H. pylori* and EBV ([@R3]--[@R7]). However, the potential carcinogenesis of viruses other than EBV associated with GC risk remains unclear until now; thus, this systematic review and meta-analysis was conducted to clarify this issue (see Figure legend Supplementary Digital Content 6, <http://links.lww.com/CTG/A298>). This systematic review and meta-analysis demonstrated that HBV, HCMV, HPV, and JCV are each associated with a statistically significantly increased risk of GC.

As a causative pathogen for hepatocellular carcinoma, HBV infection was shown to be associated with the risk of GC in some sporadic studies ([@R9],[@R57]). One meta‐analysis that included 3 case--control studies and 5 cohort studies also found that HBV infection is associated with a higher risk for GC (OR = 1.23, 95% CI  1.10--1.37) ([@R58]). As shown in this study, HBV DNA was investigated directly in gastric mucosa tissue by polymerase chain reaction method only in 2 studies with the low positive rate (0%--3.2% in GC), which was consistent with a previous study ([@R59]). In addition, the prevalence of HBV might be underestimated for studies that applied serologic assay due to the existence of occult HBV infection in which circulating hepatitis B surface antigen is absent ([@R60]). However, HBV serologic assay are still irreplaceable effective method to evaluate the status of HBV infection currently, and low prevalence rates of occult HBV infection has been reported in Asia, where most of the studies included in this meta-analysis were performed ([@R61]--[@R63]).

As one of the 8 well-known herpes viruses, HCMV infection has been reported in immunocompetent patients with gastrointestinal disease such as gastritis, and its appearance was also detected in patients with carcinomas such as colon cancer ([@R64]--[@R66]). Michaelis et al. reported that HCMV might accelerate malignant process by strengthening tumor inflammation, which indicated its role in cancer ([@R65]). Our study demonstrated that the HCMV is associated with the risk of GC and the positivity of HCMV in GC tissues was higher than any controls especially. HCMV infection might contribute to gastritis and GC subsequently ([@R10]).

The role of HPV in the etiology of cervical cancer has been established, in addition to anal and colorectal cancers potentially ([@R67]--[@R69]). Our study verified the association between the prevalence of HPV (especially HPV-16, a high-risk subtype of HPV) and GC, and the pooled HPV prevalence in GC was 23.6%, no obvious difference from the previous report ([@R70]). Although HPV serologic test was considered as a good marker for HPV detection, significant association between HPV infection and the risk of GC was observed in gastric tissues by comparison with serum samples ([@R71]). Mechanisms of HPV escaping from the host immune system might explain this result ([@R72]). As a risk factor of malignant neoplasia of the digestive tract with epithelial mucosa, HPV-16 might play a role in the development of GC initiate with infecting gastric glandular epithelium cells ([@R13]).

Significant association between infection with HTLV-1 and reduced risk of GC was suggested in several studies ([@R73]--[@R75]). In our meta-analysis, no causal association between HTLV-1 infection and GC was found. However, correlation between HTLV-1 and gastric carcinogenesis was verified in another meta‐analysis, which included 3 cohort studies that inferred that HTLV-1 infection reduces the risk of GC by intervening *H. pylori* infection and proliferation possibly ([@R76]).

In addition, there are some other viruses, such as JCV, which belong to the polyomavirus family, were included in our study. The presence of JCV has been detected in the normal gastrointestinal tract and colon cancer in humans ([@R77],[@R78]). In our study, the prevalence of JCV was associated with increased risk of GC. The presence of JCV transforming antigen was identified in all included studies, because transforming antigen, which is encoded by all polyomaviruses, was supposed to bind and inactivate tumor suppressor genes resulting in genomic instability, an important event in the oncogenesis progression ([@R23],[@R24],[@R28],[@R29],[@R33],[@R38],[@R41],[@R42],[@R48]).

Strengths and Limitations {#s4-1}
-------------------------

To our knowledge, this study was the first meta-analysis to systematically evaluate the associations between the prevalence of viruses other than EBV and GC till now. However, because of limited published data, differences in sensitivity of test methods and test samples, sample size, and environmental or geographical factors, significant heterogeneity existed. Because of the insufficient number of included studies, meta-analysis was impossible for some viruses. Moreover, because of the property of study design and almost included studies did not take *H. pylori* or EBV coinfection into consideration, it was hard to determine the causal relationship between infection of viruses and risk of GC.

However, as one of the infection-associated malignancies, the development of GC is a multifactorial and multistep process. Several studies have shown that significant difference in *H. pylori* prevalence between the GC and any controls was not found, although *H. pylori* is a well-known carcinogenic associated with GC, and its prevalence is very common ([@R3],[@R4],[@R26],[@R32],[@R79]--[@R81]). We reanalyzed after excluding subjects with known *H. pylori* and EBV positive for studies involving HBV, HCMV, HPV, and JCV, and their relationships with the increased risk of GC had not changed. Wei et al. believed that evidence supporting the interaction between HBV and *H. pylori* was insufficient ([@R9],[@R82],[@R83]). Fattahi et al. found that HCMV viral loads were much higher in *H. pylori*-negative tissues compared with those in *H. pylori*-positive tissues, and the prevalence of *H. pylori* was lower in tumor tissues than that in nontumor tissues for GC ([@R26],[@R84]). No correlation between HPV and *H. pylori* or EBV infection in gastric carcinogenesis was found in previous studies too ([@R12],[@R13],[@R49]).

CONCLUSION {#s5}
==========

In short, this study demonstrated that HBV, HCMV, HPV, or JCV were more prevalent in GC. However, the causal relationship between infection of HBV, HCMV, HPV, or JCV and risk of GC remains inconclusive, and further investigations are required (see PRISMA checklist 2009, Supplementary Digital Content 7, <http://links.lww.com/CTG/A333>).
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